Radnostix Q2 FY26 net loss widens to $881,997; sale of product drops 27% to $2.67 million

• Radnostix posted a net loss of $881,997 for the quarter ended June 30, 2026, widening from a net loss of $160,785.
• Sales fell 27% to $2.67 million, hit by lost Theranostics sales tied to two voluntary product recalls in January-February 2026.
• Gross profit dropped 37% to $1.36 million; gross margin narrowed 8 percentage points to 51%.
• Cash and cash equivalents slid 29% to $1.2 million at June 30, 2026; net cash used in operating activities was $686,000.
• Borrowed $500,000 under a 2026 Promissory Note; capsule inventory was restored in late June, with sales normalized in July.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radnostix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-027385), on August 12, 2026, and is solely responsible for the information contained therein.